AbbVie Partners with Alloy Therapeutics to Develop Next-Gen Antibody Platform

AbbVie and Alloy Therapeutics have inked a deal to develop a next-gen antibody platform, aiming to discover potent and specific antibodies for targets that current technologies struggle to address. Under the multi-year agreement, Alloy will receive an upfront payment and an additional payment tied to delivering the platform to AbbVie. This deal gives AbbVie access to the ATX-Gx platform, used by over 200 partners for therapeutic discovery programs.